Page 7 - FLIPBOOK
P. 7
Metastatic prostate cancer: what do we know?
• Androgen deprivation therapy remains a fixed part of therapy 1,2
• At least 7 drugs work in relapsed disease 1,2
– Abiraterone
– Enzalutamide, apalutamide, darolutamide
– Docetaxel, cabazitaxel
– Radium-223
– PARP inhibitors
• Using at least 4 of these upfront improve survival 1,2
– Docetaxel
– Abiraterone
– Enzalutamide, apalutamide
• Radiotherapy improves survival in low volume disease 3
PARP, poly ADP ribose polymerase.
1. Teo MY, et al. Annu Rev Med. 2017;70:479–499; 2. Nuhn P, et al. Eur Urol. 2019;75(1):88–99; 3. Parker CC, et al. Lancet. 2018;392(10162):2353–2366.
